1,063 results on '"Lorigan P"'
Search Results
2. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
- Author
-
Rasco, Drew W, Medina, Theresa, Corrie, Pippa, Pavlick, Anna C, Middleton, Mark R, Lorigan, Paul, Hebert, Chris, Plummer, Ruth, Larkin, James, Agarwala, Sanjiv S, Daud, Adil I, Qiu, Jiaheng, Bozon, Viviana, Kneissl, Michelle, Barry, Elly, and Olszanski, Anthony J
- Subjects
Humans ,Neoplasms ,Melanoma ,Skin Neoplasms ,Neoplasms ,Second Primary ,Proto-Oncogene Proteins B-raf ,Mitogen-Activated Protein Kinase Kinases ,Protein Kinase Inhibitors ,Maximum Tolerated Dose ,Adult ,BRAF ,Pan-RAF inhibitor ,Phase 1 ,Tovorafenib ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Pharmacology and Pharmaceutical Sciences ,Oncology & Carcinogenesis - Abstract
PurposeGenomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor. This first-in-human phase 1 study explored the safety and antitumor activity of tovorafenib.MethodsThis two-part study in adult patients with relapsed or refractory advanced solid tumors included a dose escalation phase and a dose expansion phase including molecularly defined cohorts of patients with melanoma. Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine the maximum-tolerated and recommended phase 2 dose (RP2D) on these schedules. Secondary objectives included evaluation of antitumor activity and tovorafenib pharmacokinetics.ResultsTovorafenib was administered to 149 patients (Q2D n = 110, QW n = 39). The RP2D of tovorafenib was defined as 200 mg Q2D or 600 mg QW. In the dose expansion phase, 58 (73%) of 80 patients in Q2D cohorts and 9 (47%) of 19 in the QW cohort had grade ≥ 3 adverse events. The most common of these overall were anemia (14 patients, 14%) and maculo-papular rash (8 patients, 8%). Responses were seen in 10 (15%) of 68 evaluable patients in the Q2D expansion phase, including in 8 of 16 (50%) patients with BRAF mutation-positive melanoma naïve to RAF and MEK inhibitors. In the QW dose expansion phase, there were no responses in 17 evaluable patients with NRAS mutation-positive melanoma naïve to RAF and MEK inhibitors; 9 patients (53%) had a best response of stable disease. QW dose administration was associated with minimal accumulation of tovorafenib in systemic circulation in the dose range of 400-800 mg.ConclusionsThe safety profile of both schedules was acceptable, with QW dosing at the RP2D of 600 mg QW preferred for future clinical studies. Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.ClinicaltrialsGov identifierNCT01425008.
- Published
- 2023
3. Interactions between reptiles and people: a perspective from wildlife rehabilitation records
- Author
-
Teagan Pyne, Ron Haering, Aditi Sriram, Shona Lorigan, Richard Shine, and Chris J. Jolly
- Subjects
conservation ,lizard ,Reptilia ,rescue ,snake ,Squamata ,Science - Abstract
As urbanization expands globally, human–wildlife interactions will inevitably increase. Here, we analysed 10 years of wildlife rehabilitation records of squamate (snake and lizard) reptiles (n = 37 075) from the Greater Sydney region, New South Wales, Australia, to explore their value to address management and conservation issues. Rescues were highly non-random regarding taxonomic focus, spatial occurrences and temporal trends due to the combined influence of (i) reptile phenology and behaviour and (ii) human perceptions of reptiles. Seasonal peaks in rescues reflect reptile and, to a lesser extent, human activity. Spatial patterns of rescues were informative about distributions and presence of easily identified taxa but were primarily driven by human presence. Larger squamate species were rescued more frequently, potentially reflecting a perception of greater danger or rescue priority. While uncommon species were often misidentified, accurate reports of these taxa may guide targeted surveys. The value of these data for conservation and management could be enhanced by emphasizing reptile identification training of volunteers and use of applications for informed species identification. Wildlife rehabilitation data offer a cost-effective means of quantifying thousands of human–reptile interactions, identifying foci (in both time and space) of human–wildlife conflict such as snakebite risk and roadkill-related reptile mortality.
- Published
- 2024
- Full Text
- View/download PDF
4. Mining nucleic acid 'omics' to boost liquid biopsy in cancer
- Author
-
Ann Tivey, Rebecca J. Lee, Alexandra Clipson, Steven M. Hill, Paul Lorigan, Dominic G. Rothwell, Caroline Dive, and Florent Mouliere
- Subjects
Medicine (General) ,R5-920 - Abstract
Summary: Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions about clinical care. To achieve precision medicine, the new generation of biomarkers must reflect the spatial and temporal heterogeneity of cancer biology both between patients and within an individual patient. Mining the different layers of 'omics in a multi-modal way from a minimally invasive, easily repeatable, liquid biopsy has increasing potential in a range of clinical applications, and for improving our understanding of treatment response and resistance. Here, we detail the recent developments and methods allowing exploration of genomic, epigenomic, transcriptomic, and fragmentomic layers of 'omics from liquid biopsy, and their integration in a range of applications. We also consider the specific challenges that are posed by the clinical implementation of multi-omic liquid biopsies.
- Published
- 2024
- Full Text
- View/download PDF
5. Evaluation of the effectiveness of Washington State’s digital COVID-19 exposure notification system over one pandemic year
- Author
-
Adam S. Elder, Cory J. Arrouzet, Ljubomir Miljacic, Bryant T. Karras, Amanda Higgins, Laura M. West, Daniel Lorigan, Debra Revere, Nayak Polissar, Courtney D. Segal, William B. Lober, and Janet G. Baseman
- Subjects
digital exposure notifications ,data privacy ,non-pharmaceutical interventions ,COVID-19 ,outbreak investigation and response ,Public aspects of medicine ,RA1-1270 - Abstract
IntroductionDigital exposure notifications are a novel public health intervention used during the COVID-19 pandemic to alert users of possible COVID-19 exposure. We seek to quantify the effectiveness of Washington State’s digital exposure notification system, WA Notify, as measured by the number of COVID-19 cases averted during a 1-year period.MethodsWhile maintaining individuals’ privacy, WA Notify collected data that could be used to evaluate the system’s effectiveness. This article uses these and other data and builds on a previous model to estimate the number of cases averted by WA Notify. Novel estimates of some model parameters are possible because of improvements in the quality and breadth of data reported by WA Notify.ResultsWe estimate that WA Notify averted 64,000 (sensitivity analysis: 35,000–92,000) COVID-19 cases in Washington State during the study period from 1 March 2021 to 28 February 2022. During this period, there were an estimated 1,089,000 exposure notifications generated and 155,000 cases reported to WA Notify. During the last 78 days of the study period, the median estimated number of daily active users was 1,740,000.DiscussionWe believe WA Notify reduced the impact of the COVID-19 pandemic in Washington State and that similar systems could reduce the impact of future communicable disease outbreaks.
- Published
- 2024
- Full Text
- View/download PDF
6. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
- Author
-
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty
- Subjects
Medicine (General) ,R5-920 - Published
- 2024
- Full Text
- View/download PDF
7. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
- Author
-
Dummer, Reinhard, Long, Georgina V, Robert, Caroline, Tawbi, Hussein A, Flaherty, Keith T, Ascierto, Paolo A, Nathan, Paul D, Rutkowski, Piotr, Leonov, Oleg, Dutriaux, Caroline, Mandalà, Mario, Lorigan, Paul, Ferrucci, Pier Francesco, Grob, Jean Jacques, Meyer, Nicolas, Gogas, Helen, Stroyakovskiy, Daniil, Arance, Ana, Brase, Jan C, Green, Steven, Haas, Tomas, Masood, Aisha, Gasal, Eduard, Ribas, Antoni, and Schadendorf, Dirk
- Subjects
Clinical Research ,Genetics ,Cancer ,Clinical Trials and Supportive Activities ,Human Genome ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adolescent ,Adult ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Imidazoles ,Melanoma ,Mutation ,Neoplasms ,Second Primary ,Oximes ,Proto-Oncogene Proteins B-raf ,Pyridones ,Pyrimidinones ,Receptors ,Death Domain ,Skin Neoplasms ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposePreclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600-mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, an anti-programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600-mutant unresectable or metastatic melanoma.MethodsPatients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram. Participants were age ≥ 18 years with unresectable or metastatic BRAF V600-mutant melanoma. The primary end point was investigator-assessed progression-free survival. Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692).ResultsAt data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]). The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively. Grade ≥ 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm.ConclusionThe study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.
- Published
- 2022
8. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
- Author
-
Wong, Chun Wai, Evangelou, Christos, Sefton, Kieran N., Leshem, Rotem, Zhang, Wei, Gopalan, Vishaka, Chattrakarn, Sorayut, Fernandez Carro, Macarena Lucia, Uzuner, Erez, Mole, Holly, Wilcock, Daniel J., Smith, Michael P., Sergiou, Kleita, Telfer, Brian A., Isaac, Dervla T., Liu, Chang, Perl, Nicholas R., Marie, Kerrie, Lorigan, Paul, Williams, Kaye J., Rao, Patricia E., Nagaraju, Raghavendar T., Niepel, Mario, and Hurlstone, Adam F. L.
- Published
- 2023
- Full Text
- View/download PDF
9. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
- Author
-
Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester, and Ascierto, Paolo A.
- Published
- 2023
- Full Text
- View/download PDF
10. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
- Author
-
Visconti, Alessia, Rossi, Niccolò, Deriš, Helena, Lee, Karla A, Hanić, Maja, Trbojević-Akmačić, Irena, Thomas, Andrew M., Bolte, Laura A., Björk, Johannes R., Hooiveld-Noeken, Jahlisa S., Board, Ruth, Harland, Mark, Newton-Bishop, Julia, Harries, Mark, Sacco, Joseph J., Lorigan, Paul, Shaw, Heather M., de Vries, Elisabeth G.E., Fehrmann, Rudolf S.N., Weersma, Rinse K., Spector, Tim D., Nathan, Paul, Hospers, Geke A. P., Sasieni, Peter, Bataille, Veronique, Lauc, Gordan, and Falchi, Mario
- Published
- 2023
- Full Text
- View/download PDF
11. A hydrophilic microenvironment in the substrate-translocating groove of the YidC membrane insertase is essential for enzyme function
- Author
-
Chen, Yuanyuan, Sotomayor, Marcos, Capponi, Sara, Hariharan, Balasubramani, Sahu, Indra D, Haase, Maximilian, Lorigan, Gary A, Kuhn, Andreas, White, Stephen H, and Dalbey, Ross E
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Infectious Diseases ,Bacillus subtilis ,Cell Membrane ,Escherichia coli ,Escherichia coli Proteins ,Hydrophobic and Hydrophilic Interactions ,Membrane Transport Proteins ,Structure-Activity Relationship ,S. mutans ,YidC ,membrane biogenesis ,membrane transport ,molecular dynamics ,Chemical Sciences ,Medical and Health Sciences ,Biochemistry & Molecular Biology ,Biological sciences ,Biomedical and clinical sciences ,Chemical sciences - Abstract
The YidC family of proteins are membrane insertases that catalyze the translocation of the periplasmic domain of membrane proteins via a hydrophilic groove located within the inner leaflet of the membrane. All homologs have a strictly conserved, positively charged residue in the center of this groove. In Bacillus subtilis, the positively charged residue has been proposed to be essential for interacting with negatively charged residues of the substrate, supporting a hypothesis that YidC catalyzes insertion via an early-step electrostatic attraction mechanism. Here, we provide data suggesting that the positively charged residue is important not for its charge but for increasing the hydrophilicity of the groove. We found that the positively charged residue is dispensable for Escherichia coli YidC function when an adjacent residue at position 517 was hydrophilic or aromatic, but was essential when the adjacent residue was apolar. Additionally, solvent accessibility studies support the idea that the conserved positively charged residue functions to keep the top and middle of the groove sufficiently hydrated. Moreover, we demonstrate that both the E. coli and Streptococcus mutans YidC homologs are functional when the strictly conserved arginine is replaced with a negatively charged residue, provided proper stabilization from neighboring residues. These combined results show that the positively charged residue functions to maintain a hydrophilic microenvironment in the groove necessary for the insertase activity, rather than to form electrostatic interactions with the substrates.
- Published
- 2022
12. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
- Author
-
Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, and Paolo A. Ascierto
- Subjects
Diabetes ,Nivolumab + relatlimab ,Melanoma ,LDH ,Medicine - Abstract
Abstract Background The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes. Method To evaluate the impact of diabetes on oncological outcomes of patients with advanced melanoma treated with nivolumab plus the LAG3 inhibitor relatlimab we performed a retrospective multicenter study. Results Overall, 129 patients were included: 88 without diabetes before the treatment, 37 who were diagnosed with type 2 diabetes before the start of treatment, and 4 without diabetes before treatment who developed immune checkpoint inhibitor-induced diabetes (ICI-DM). PFS was 21.71 months (95% CI: 15.61–27.81) in patients without diabetes, 10.23 months (95% CI: 5.81–14.66) in patients with type 2 diabetes, and 50.85 months (95% CI: 23.04–78.65) in patients who developed ICI-DM. OS was 37.94 months (95% CI: 31.02–44.85) in patients without diabetes, 22.12 months (95% CI: 14.41–29.85) in those with type 2 diabetes and 57.64 months (95% CI: 42.29–72.99) in those who developed ICI-DM. Multivariate analysis showed that the presence of diabetes and LDH was correlated with OS and PFS. The mean OS was 64.63 months in subjects with low levels of glucose ( 1.5) had a worse prognosis than those whose glucose level had not increased. This result was observed also in subgroups treated either in first line or further lines. Patients who developed ICI-DM during the study period had better outcomes than the overall population and patients without diabetes. Conclusions LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG3 in tumor tissue. Higher level evidence should be obtained.
- Published
- 2023
- Full Text
- View/download PDF
13. The Wetland Intrinsic Potential tool: mapping wetland intrinsic potential through machine learning of multi-scale remote sensing proxies of wetland indicators
- Author
-
M. Halabisky, D. Miller, A. J. Stewart, A. Yahnke, D. Lorigan, T. Brasel, and L. M. Moskal
- Subjects
Technology ,Environmental technology. Sanitary engineering ,TD1-1066 ,Geography. Anthropology. Recreation ,Environmental sciences ,GE1-350 - Abstract
Accurate, unbiased wetland inventories are critical to monitor and protect wetlands from future harm or land conversion. However, most wetland inventories are constructed through manual image interpretation or automated classification of multi-band imagery and are biased towards wetlands that are easy to directly detect in aerial and satellite imagery. Wetlands that are obscured by forest canopy, that occur ephemerally, and that have no visible standing water are, therefore, often missing from wetland maps. To aid in the detection of these cryptic wetlands, we developed the Wetland Intrinsic Potential (WIP) tool, based on a wetland-indicator framework commonly used on the ground to detect wetlands through the presence of hydrophytic vegetation, hydrology, and hydric soils. Our tool uses a random forest model with spatially explicit input variables that represent all three wetland indicators, including novel multi-scale topographic indicators that represent the processes that drive wetland formation, to derive a map of wetland probability. With the ability to include multi-scale topographic indicators that help identify cryptic wetlands, the WIP tool can identify areas conducive to wetland formation while providing a flexible approach that can be adapted to diverse landscapes. For a study area in the Hoh River watershed in western Washington, USA, classification of the output probability with a threshold of 0.5 provided an overall accuracy of 91.97 %. Compared to the National Wetlands Inventory, the classified WIP tool output identified over 2 times the wetland area and reduced errors of omission from 47.5 % to 14.1 % but increased errors of commission from 1.9 % to 10.5 %. The WIP tool is implemented as an ArcGIS toolbox using a combination of R and Python scripts.
- Published
- 2023
- Full Text
- View/download PDF
14. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
- Author
-
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, Rotem Leshem, Wei Zhang, Vishaka Gopalan, Sorayut Chattrakarn, Macarena Lucia Fernandez Carro, Erez Uzuner, Holly Mole, Daniel J. Wilcock, Michael P. Smith, Kleita Sergiou, Brian A. Telfer, Dervla T. Isaac, Chang Liu, Nicholas R. Perl, Kerrie Marie, Paul Lorigan, Kaye J. Williams, Patricia E. Rao, Raghavendar T. Nagaraju, Mario Niepel, and Adam F. L. Hurlstone
- Subjects
Science - Abstract
Abstract Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular immunity, can promote ICBT resistance. Using syngeneic mouse tumour models, we confirm that chronic IFNγ exposure confers resistance to immunotherapy targeting PD-1 (α-PD-1) in immunocompetent female mice. We observe upregulation of poly-ADP ribosyl polymerase 14 (PARP14) in chronic IFNγ-treated cancer cell models, in patient melanoma with elevated IFNG expression, and in melanoma cell cultures from ICBT-progressing lesions characterised by elevated IFNγ signalling. Effector T cell infiltration is enhanced in tumours derived from cells pre-treated with IFNγ in immunocompetent female mice when PARP14 is pharmacologically inhibited or knocked down, while the presence of regulatory T cells is decreased, leading to restoration of α-PD-1 sensitivity. Finally, we determine that tumours which spontaneously relapse in immunocompetent female mice following α-PD-1 therapy upregulate IFNγ signalling and can also be re-sensitised upon receiving PARP14 inhibitor treatment, establishing PARP14 as an actionable target to reverse IFNγ-driven ICBT resistance.
- Published
- 2023
- Full Text
- View/download PDF
15. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series
- Author
-
Weaver, Jamie MJ, Dodd, Katie, Knight, Tom, Chaudhri, Mehek, Khera, Raj, Lilleker, James B, Roberts, Mark, Lorigan, Paul, and Cooksley, Tim
- Published
- 2023
- Full Text
- View/download PDF
16. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context
- Author
-
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty
- Subjects
Adjuvant therapy ,BRAF V600 mutation ,Melanoma ,PD-1 ,Dabrafenib/trametinib ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers. Methods: This multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1 between Jul 2015 and Oct 2022. The primary endpoint was relapse-free survival (RFS). Secondary endpoints included overall survival (OS), recurrence pattern and toxicity. Findings: We included 598 patients with stage III BRAF V600-mutant melanoma who received either adjuvant D/T (n = 393 [66%]) or PD-1 (n = 205 [34%]) post definitive surgery between Jul 2015 and Oct 2022. At a median follow-up of 33 months (IQR 21–43), the median RFS was 51.0 months (95% CI 41.0-not reached [NR]) in the D/T group, significantly longer than PD-1 (44.8 months [95% CI 28.5-NR]) (univariate: HR 0.66, 95% CI 0.50–0.87, P = 0.003; multivariate: HR 0.58, 95% CI 0.39–0.86, P = 0.007), with comparable OS with PD-1 (multivariate, HR 0.90, 95% CI 0.48–1.70, P = 0.75). Similar findings were observed using a restricted-mean-survival-time model. Among those who experienced recurrence, the proportion of distant metastases was higher in the D/T cohort. D/T had a higher incidence of treatment modification due to adverse events (AEs) than PD-1, but fewer persistent AEs. Interpretation: In patients with stage III BRAF V600-mutant melanoma post definitive surgery, D/T yielded better RFS than PD-1, with higher transient but lower persistent toxicity, and comparable OS. D/T seems to provide a better outcome compared with PD-1, but a longer follow-up and ideally a large prospective trial are needed. Funding: Dr. Xue Bai was supported by the Beijing Hospitals Authority Youth Programme (QMS20211101) for her efforts devoted to this study. Dr. Keith T. Flaherty was funded by Adelson Medical Research Foundation for the efforts devoted to this study.
- Published
- 2023
- Full Text
- View/download PDF
17. Regional oceanography affects humpback whale entanglements in set fishing gear
- Author
-
Hayden T. Schilling, Adelaide V. Dedden, Susan Crocetti, Geoff Liggins, Shona Lorigan, Andrew Marshall, Tracey L. Rogers, Amandine Schaeffer, Iain M. Suthers, and Daniel D. Johnson
- Subjects
bycatch ,dynamic ocean management ,east Australian current ,fish traps ,fisher‐wildlife interactions ,Megaptera novaengliae ,Ecology ,QH540-549.5 ,General. Including nature conservation, geographical distribution ,QH1-199.5 - Abstract
Abstract Humpback whales Megaptera novaengliae undertake annual migrations along eastern Australia, where they can be susceptible to entanglement in set fishing gear. This can potentially result in both sublethal and fatal outcomes for the whales, and financial losses for the fishing industry, including loss of gear and catch. Interannual fluctuations in entanglement records suggest that dynamic oceanographic features may be associated with the whales' migration path, and therefore, risk of entanglement. Using records of demersal fish traps off the coast of New South Wales (NSW), we identify two areas of high fishing pressure and entanglement risk overlap. Within each area, we combine entanglement observations with metrics associated with the East Australian Current (EAC) and climate (i.e., southern oscillation index). We show that the strength and position of the EAC was associated with the likelihood of entanglement in set fishing gear. In northern NSW (30.3° S), entanglement risk was highest between July and October when the EAC is relatively close to the coast. In contrast, there was no evidence suggesting that oceanography further south in the separation zone of the EAC (33.8° S) was associated with risk of entanglement. In the years following a strongly negative SOI (i.e., El Niño events), entanglement risk was also reduced. While we provide clear linkages with regional oceanographic dynamics and entanglement risk off NSW, if a dynamic ocean management approach to reducing entanglements is to be realized, further research into the fine‐scale movements of humpback whales is needed.
- Published
- 2023
- Full Text
- View/download PDF
18. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
- Author
-
Garbe, Claus, Dummer, Reinhard, Amaral, Teresa, Amaria, Rodabe N., Ascierto, Paolo A., Burton, Elizabeth M., Dreno, Brigitte, Eggermont, Alexander M. M., Hauschild, Axel, Hoeller, Christoph, Kaufmann, Roland, Lebbe, Celeste, Mandala, Mario, Menzies, Alexander M., Moreno, David, Michielin, Olivier, Nathan, Paul, Patel, Sapna P., Robert, Caroline, Schadendorf, Dirk, Lorigan, Paul C., Scolyer, Richard A., Tawbi, Hussein A., van de Wiel, Bart A., Blank, Christian, and Long, Georgina V.
- Published
- 2023
- Full Text
- View/download PDF
19. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
- Author
-
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, and Kotapati Srividya
- Subjects
Ipilimumab ,Randomized clinical trial ,EORTC QLQ-C30 ,Advanced melanoma ,Health-related quality of life ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s 12 week treatment induction period. Methods The Phase III clinical trial (MDX010-20) was a double-blind, fixed dose study in 676 previously treated advanced unresectable stage III or IV melanoma patients. Patients were randomized 3:1:1 to receive either ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (peptide vaccine; 1 mg q3w x 4 doses; ipilimumab plus gp100, n = 403); gp100 vaccine + placebo (gp100 alone, n = 136); or ipilimumab + placebo (ipilimumab alone, n = 137). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assessed HRQL. Baseline to Week 12 changes in EORTC QLQ-C30 function, global health status, and symptom scores were analyzed for ipilimumab with/without gp100 vaccine compared to gp100 alone. Mean change in scores were categorized “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much” (>20). Results In the ipilimumab plus gp100 and ipilimumab alone groups, mean changes from baseline to Week 12 generally indicated “no change” or “a little” impairment across EORTC QLQ-C30 global health status, function, and symptom subscales. Significant differences in constipation, favoring ipilimumab, were observed (p Conclusions Ipilimumab with/without gp100 vaccine does not have a significant negative HRQL impact during the treatment induction phase relative to gp100 alone in stage III or IV melanoma patients. Trial registration Clinicaltrials.gov identification number NCT00094653
- Published
- 2012
- Full Text
- View/download PDF
20. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
- Author
-
Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Irena Trbojević-Akmačić, Andrew M. Thomas, Laura A. Bolte, Johannes R. Björk, Jahlisa S. Hooiveld-Noeken, Ruth Board, Mark Harland, Julia Newton-Bishop, Mark Harries, Joseph J. Sacco, Paul Lorigan, Heather M. Shaw, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann, Rinse K. Weersma, Tim D. Spector, Paul Nathan, Geke A. P. Hospers, Peter Sasieni, Veronique Bataille, Gordan Lauc, and Mario Falchi
- Subjects
Melanoma ,Immune checkpoint inhibitors ,Total serum N-glycomics ,Response ,Survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs. Glycosylation affects proteins and lipids’ structure and functions. Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response. Methods We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries. Samples were collected before and during ICI treatment. Results We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone. Conclusion While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
- Published
- 2023
- Full Text
- View/download PDF
21. Studying Conformational Properties of Transmembrane Domain of KCNE3 in a Lipid Bilayer Membrane Using Molecular Dynamics Simulations
- Author
-
Anna Clara Miranda Moura, Isaac K. Asare, Mateo Fernandez Cruz, Antonio Javier Franco Aguado, Kaeleigh Dyan Tuck, Conner C. Campbell, Matthew W. Scheyer, Ikponwmosa Obaseki, Steve Alston, Andrea N. Kravats, Charles R. Sanders, Gary A. Lorigan, and Indra D. Sahu
- Subjects
molecular dynamics simulation ,KCNE3 transmembrane domain ,conformational dynamics ,lipid bilayers ,Chemical technology ,TP1-1185 ,Chemical engineering ,TP155-156 - Abstract
KCNE3 is a single-pass integral membrane protein that regulates numerous voltage-gated potassium channel functions such as KCNQ1. Previous solution NMR studies suggested a moderate degree of curved α-helical structure in the transmembrane domain (TMD) of KCNE3 in lyso-myristoylphosphatidylcholine (LMPC) micelles and isotropic bicelles with the residues T71, S74 and G78 situated along the concave face of the curved helix. During the interaction of KCNE3 and KCNQ1, KCNE3 pushes its transmembrane domain against KCNQ1 to lock the voltage sensor in its depolarized conformation. A cryo-EM study of KCNE3 complexed with KCNQ1 in nanodiscs suggested a deviation of the KCNE3 structure from its independent structure in isotropic bicelles. Despite the biological significance of KCNE3 TMD, the conformational properties of KCNE3 are poorly understood. Here, all atom molecular dynamics (MD) simulations were utilized to investigate the conformational dynamics of the transmembrane domain of KCNE3 in a lipid bilayer containing a mixture of POPC and POPG lipids (3:1). Further, the effect of the interaction impairing mutations (V72A, I76A and F68A) on the conformational properties of the KCNE3 TMD in lipid bilayers was investigated. Our MD simulation results suggest that the KCNE3 TMD adopts a nearly linear α helical structural conformation in POPC-POPG lipid bilayers. Additionally, the results showed no significant change in the nearly linear α-helical conformation of KCNE3 TMD in the presence of interaction impairing mutations within the sampled time frame. The KCNE3 TMD is more stable with lower flexibility in comparison to the N-terminal and C-terminal of KCNE3 in lipid bilayers. The overall conformational flexibility of KCNE3 also varies in the presence of the interaction-impairing mutations. The MD simulation data further suggest that the membrane bilayer width is similar for wild-type KCNE3 and KCNE3 containing mutations. The Z-distance measurement data revealed that the TMD residue site A69 is close to the lipid bilayer center, and residue sites S57 and S82 are close to the surfaces of the lipid bilayer membrane for wild-type KCNE3 and KCNE3 containing interaction-impairing mutations. These results agree with earlier KCNE3 biophysical studies. The results of these MD simulations will provide complementary data to the experimental outcomes of KCNE3 to help understand its conformational dynamic properties in a more native lipid bilayer environment.
- Published
- 2024
- Full Text
- View/download PDF
22. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
- Author
-
Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, and Shaad E Abedin
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve outcomes. Tebentafusp is a first-in-class gp100×CD3 ImmTAC bispecific that demonstrated overall survival (OS) benefit (HR 0.51) in metastatic uveal melanoma despite a modest overall response rate of 9%. This phase 1b trial evaluated the safety and initial efficacy of tebentafusp in combination with durvalumab (anti-programmed death ligand 1 (PDL1)) and/or tremelimumab (anti-cytotoxic T lymphocyte-associated antigen 4) in patients with metastatic cutaneous melanoma (mCM), the majority of whom progressed on prior checkpoint inhibitors.Methods In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A*02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and/or tremelimumab starting day 15 of each cycle. The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose for each combination. Efficacy analyses were performed in all tebentafusp with durvalumab±tremelimumab treated patients with a sensitivity analysis in those who progressed on prior anti-PD(L)1 therapy.Results 85 patients were assigned to receive tebentafusp in combination with durvalumab (n=43), tremelimumab (n=13), or durvalumab and tremelimumab (n=29). Patients were heavily pretreated with a median of 3 prior lines of therapy, including 76 (89%) who received prior anti-PD(L)1. Maximum target doses of tebentafusp (68 mcg) alone or in combination with durvalumab (20 mg/kg) and tremelimumab (1 mg/kg) were tolerated; MTD was not formally identified for any arm. Adverse event profile was consistent with each individual therapy and there were no new safety signals nor treatment-related deaths. In the efficacy subset (n=72), the response rate was 14%, tumor shrinkage rate was 41% and 1-year OS rate was 76% (95% CI: 70% to 81%). The 1-year OS for triplet combination (79%; 95% CI: 71% to 86%) was similar to tebentafusp plus durvalumab (74%; 95% CI: 67% to 80%).Conclusion At maximum target doses, the safety of tebentafusp with checkpoint inhibitors was consistent with safety of each individual therapy. Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1.Trial registration number NCT02535078.
- Published
- 2023
- Full Text
- View/download PDF
23. Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
- Author
-
Woof, Victoria G., Lee, Rebecca J., Lorigan, Paul, and French, David P.
- Published
- 2022
- Full Text
- View/download PDF
24. Completion of the Vimentin Rod Domain Structure Using Experimental Restraints: A New Tool for Exploring Intermediate Filament Assembly and Mutations
- Author
-
Gae, David D, Budamagunta, Madhu S, Hess, John F, McCarrick, Robert M, Lorigan, Gary A, FitzGerald, Paul G, and Voss, John C
- Subjects
Biochemistry and Cell Biology ,Chemical Sciences ,Biological Sciences ,Electron Spin Resonance Spectroscopy ,Humans ,Models ,Molecular ,Molecular Dynamics Simulation ,Mutation ,Protein Domains ,Protein Structure ,Secondary ,Spin Labels ,Vimentin ,EPR ,ESR ,UCSF chimera: macromolecular structure ,electron paramagnetic resonance ,intermediate filaments ,molecular dynamics ,molecular modeling ,site-directed spin labeling ,vimentin ,Biophysics - Abstract
Electron paramagnetic resonance (EPR) spectroscopy of full-length vimentin and X-ray crystallography of vimentin peptides has provided concordant structural data for nearly the entire central rod domain of the protein. In this report, we use a combination of EPR spectroscopy and molecular modeling to determine the structure and dynamics of the missing region and unite the separate elements into a single structure. Validation of the linker 1-2 (L1-2) modeling approach is demonstrated by the close correlation between EPR and X-ray data in the previously solved regions. Importantly, molecular dynamic (MD) simulation of the constructed model agrees with spin label motion as determined by EPR. Furthermore, MD simulation shows L1-2 heterogeneity, with a concerted switching of states among the dimer chains. These data provide the first ever experimentally driven model of a complete intermediate filament rod domain, providing research tools for further modeling and assembly studies.
- Published
- 2019
25. Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer
- Author
-
Tinsley, N., Zhou, C., Nahm, S., Rack, S., Tan, G.C.L., Lorigan, P., Blackhall, F., and Cook, N.
- Published
- 2022
- Full Text
- View/download PDF
26. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
- Author
-
Monteiro, Cátia, Miarka, Lauritz, Perea-García, María, Priego, Neibla, García-Gómez, Pedro, Álvaro-Espinosa, Laura, de Pablos-Aragoneses, Ana, Yebra, Natalia, Retana, Diana, Baena, Patricia, Fustero-Torre, Coral, Graña-Castro, Osvaldo, Troulé, Kevin, Caleiras, Eduardo, Tezanos, Patricia, Muela, Pablo, Cintado, Elisa, Trejo, José Luis, Sepúlveda, Juan Manuel, González-León, Pedro, Jiménez-Roldán, Luis, Moreno, Luis Miguel, Esteban, Olga, Pérez-Núñez, Ángel, Hernández-Lain, Aurelio, Mazarico Gallego, José, Ferrer, Irene, Suárez, Rocío, Garrido-Martín, Eva M., Paz-Ares, Luis, Dalmasso, Celine, Cohen-Jonathan Moyal, Elizabeth, Siegfried, Aurore, Hegarty, Aisling, Keelan, Stephen, Varešlija, Damir, Young, Leonie S., Mohme, Malte, Goy, Yvonne, Wikman, Harriet, Fernández-Alén, Jose, Blasco, Guillermo, Alcázar, Lucía, Cabañuz, Clara, Grivennikov, Sergei I., Ianus, Andrada, Shemesh, Noam, Faria, Claudia C., Lee, Rebecca, Lorigan, Paul, Le Rhun, Emilie, Weller, Michael, Soffietti, Riccardo, Bertero, Luca, Ricardi, Umberto, Bosch-Barrera, Joaquim, Sais, Elia, Teixidor, Eduard, Hernández-Martínez, Alejandro, Calvo, Alfonso, Aristu, Javier, Martin, Santiago M., Gonzalez, Alvaro, Adler, Omer, Erez, Neta, and Valiente, Manuel
- Published
- 2022
- Full Text
- View/download PDF
27. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Author
-
Lee, Karla A., Thomas, Andrew Maltez, Bolte, Laura A., Björk, Johannes R., de Ruijter, Laura Kist, Armanini, Federica, Asnicar, Francesco, Blanco-Miguez, Aitor, Board, Ruth, Calbet-Llopart, Neus, Derosa, Lisa, Dhomen, Nathalie, Brooks, Kelly, Harland, Mark, Harries, Mark, Leeming, Emily R., Lorigan, Paul, Manghi, Paolo, Marais, Richard, Newton-Bishop, Julia, Nezi, Luigi, Pinto, Federica, Potrony, Miriam, Puig, Susana, Serra-Bellver, Patricio, Shaw, Heather M., Tamburini, Sabrina, Valpione, Sara, Vijay, Amrita, Waldron, Levi, Zitvogel, Laurence, Zolfo, Moreno, de Vries, Elisabeth G. E., Nathan, Paul, Fehrmann, Rudolf S. N., Bataille, Véronique, Hospers, Geke A. P., Spector, Tim D., Weersma, Rinse K., and Segata, Nicola
- Published
- 2022
- Full Text
- View/download PDF
28. Circulating Tumour DNA in Melanoma—Clinic Ready?
- Author
-
Tivey, Ann, Britton, Fiona, Scott, Julie-Ann, Rothwell, Dominic, Lorigan, Paul, and Lee, Rebecca
- Published
- 2022
- Full Text
- View/download PDF
29. Vinyl Ether Maleic Acid Polymers: Tunable Polymers for Self-Assembled Lipid Nanodiscs and Environments for Membrane Proteins.
- Author
-
Shah, Muhammad Zeeshan, Rotich, Nancy C., Okorafor, Evelyn A., Oestreicher, Zachery, Demidovich, Gabrielle, Eapen, Jeremy, Henoch, Quinton, Kilbey, Julia, Prempeh, Godfred, Bates, Alison, Page, Richard C., Lorigan, Gary A., and Konkolewicz, Dominik
- Published
- 2024
- Full Text
- View/download PDF
30. Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case
- Author
-
Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, and Yinglai Huang
- Subjects
short synacthen test ,sst ,hypophysitis ,immunotherapy ,acth deficiency ,cortisol ,immune checkpoint inhibitor ,assay ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Short synacthen tests (SST) are frequently used for assessing adrenocorticotropin hormone (ACTH) deficiency. In this study, we present the case of a 53-year-old man receiving immunotherapy for metastatic melanoma, who subsequently developed immune checkpoint inhibitor (ICI)-induced hypothyroidism and was investigated for the presence of ICI-induced hypocortisolaemia on different occasions. Despite two reassuring SSTs, he subsequently developed clinical and biochemical evidence of ACTH deficiency. The ACTH on local measurement was not conclusive in keeping with ICI-related ACTH deficiency but when repeated using an alternative assay confirmed the diagnosis. The case illustrates the evolution of ACTH deficiency and exposes the potential pitfalls of screening strategies. Two important lessons may be gleaned from this case: (i) SSTs can be normal in early cases of secondary adrenal insufficiency, for example, hypophysitis due to adrenal reserve and (ii) when there is mismatch between the clinical and biochemical presentation, the ACTH should be repeated using a different assay.
- Published
- 2023
- Full Text
- View/download PDF
31. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- Author
-
Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Wilson H, Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D, Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C, Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, Walker, Dana, Kong, George, Horak, Christine, and Weber, Jeffrey
- Subjects
Clinical Trials and Supportive Activities ,Cancer ,Patient Safety ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Administration ,Intravenous ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Immunological ,Antineoplastic Combined Chemotherapy Protocols ,Carboplatin ,Dacarbazine ,Disease Progression ,Drug Administration Schedule ,Female ,Humans ,Male ,Melanoma ,Middle Aged ,Nivolumab ,Paclitaxel ,Progression-Free Survival ,Skin Neoplasms ,Time Factors ,Young Adult ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma. Patients and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then randomly assigned 2:1 to nivolumab 3 mg/kg intravenously every 2 weeks or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 mg/m2 every 3 weeks). Patients were treated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2 years. Results Two hundred seventy-two patients were randomly assigned to nivolumab (99% treated) and 133 to ICC (77% treated). More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41% of patients treated with ICC versus 11% of patients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therapy. Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 10%) and median duration of response (32 months v 13 months) were notably higher for nivolumab versus ICC. Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v 34%). Conclusion Nivolumab demonstrated higher, more durable responses but no difference in survival compared with ICC. OS should be interpreted with caution as it was likely impacted by an increased dropout rate before treatment, which led to crossover therapy in the ICC group, and by an increased proportion of patients in the nivolumab group with poor prognostic factors.
- Published
- 2018
32. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
- Author
-
Niccolò Rossi, Karla A. Lee, Maria V. Bermudez, Alessia Visconti, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Julia Newton-Bishop, Mark Harland, Heather M. Shaw, Mark Harries, Joseph Sacco, Ruth Board, Paul Lorigan, Elisabeth G.E. de Vries, Nicola Segata, Leonie Taams, Sophie Papa, Tim D. Spector, Paul Nathan, Rinse K. Weersma, Geke A.P. Hospers, Rudolf S.N. Fehrmann, Veronique Bataille, and Mario Falchi
- Subjects
Melanoma ,Checkpoint inhibitors ,Inflammatory proteins ,Response ,Survival ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma. Methods: Study subjects were 87 patients with unresectable stage III or IV cutaneous melanoma from the multiple centres across the United Kingdom (UK) and the Netherlands (NL) who received ipilimumab, nivolumab, or pembrolizumab, or a combination of ipilimumab and nivolumab. Serum samples were collected before and during ICI therapy at follow-up visits scheduled every third week over a 12-week period. We performed targeted quantification of 92 proteins involved in inflammation and tested for association of their pre-treatment and on-treatment levels, as well as longitudinal changes, with overall response rate, progression-free survival, and overall survival. Findings: We observed consistently higher pre-treatment levels of interleukin-6 (IL-6), hepatocyte growth factor (HGF), and monocyte chemotactic protein 2 (MCP-2), in non-responders compared to responders (meta-analysis p=3.31 × 10−4, 2.29 × 10−4, and 1.02 × 10−3, respectively). Patients' stratification according to the median value of IL-6, HGF, and MCP-2 highlighted a cumulative negative effect of pre-treatment levels of the three proteins on response (p=1.13 × 10−2), with overall response rate among patients presenting with combined elevated IL-6, HGF, and MCP-2 levels being three-fold lower (26.7%) compared to patients with none of the three proteins elevated (80.0%, p=9.22 × 10−3). Longitudinal data analysis showed that on-treatment changes in circulating inflammatory proteins are not correlated with response. Interpretation: Our findings are in line with an increasing body of evidence that the pro-inflammatory cytokine IL-6 can influence response to ICI in advanced melanoma, and further support a role of circulating HGF and MCP-2 levels as prognostic biomarkers as suggested by previous smaller studies. Inflammatory proteins may serve as predictive biomarkers of ICI response and valuable targets for combination therapy. Funding: This work was supported by the Seerave Foundation and Dutch Cancer Society.
- Published
- 2022
- Full Text
- View/download PDF
33. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
- Author
-
Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., and Menzies, A.M.
- Published
- 2021
- Full Text
- View/download PDF
34. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
- Author
-
Sara Valpione, Piyushkumar A. Mundra, Elena Galvani, Luca G. Campana, Paul Lorigan, Francesco De Rosa, Avinash Gupta, John Weightman, Sarah Mills, Nathalie Dhomen, and Richard Marais
- Subjects
Science - Abstract
Precision medicine needs prognostic markers to select the patients that will benefit more from targeted therapy. Authors show here that high level of baseline T cell receptor diversity is an indicator of favourable prognosis in multiple cancer types, and monoclonal expansion of T-cells correlates with good response to immune checkpoint blockade therapy in metastatic melanoma patients.
- Published
- 2021
- Full Text
- View/download PDF
35. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
- Author
-
Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., and Springer, C.
- Published
- 2021
- Full Text
- View/download PDF
36. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study
- Author
-
Gomes, F., Lorigan, P., Woolley, S., Foden, P., Burns, K., Yorke, J., and Blackhall, F.
- Published
- 2021
- Full Text
- View/download PDF
37. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
- Author
-
Chapman, PB, Robert, C, Larkin, J, Haanen, JB, Ribas, A, Hogg, D, Hamid, O, Ascierto, PA, Testori, A, Lorigan, PC, Dummer, R, Sosman, JA, Flaherty, KT, Chang, I, Coleman, S, Caro, I, Hauschild, A, and McArthur, GA
- Subjects
Clinical Research ,Cancer ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Antineoplastic Agents ,Alkylating ,Dacarbazine ,Enzyme Inhibitors ,Female ,Humans ,Indoles ,Kaplan-Meier Estimate ,Male ,Melanoma ,Middle Aged ,Mutation ,Proto-Oncogene Proteins B-raf ,Skin Neoplasms ,Sulfonamides ,Treatment Outcome ,Vemurafenib ,Young Adult ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Published
- 2017
38. Thermodynamic Details of Pinholin S2168 Activation Revealed Using Alchemical Free Energy Simulations
- Author
-
Kalbfleisch, Theodore S., Ahammad, Tanbir, Lorigan, Gary A., and Jaeger, Vance W.
- Abstract
Pinholin S2168 is a viral integral membrane protein whose function is to form nanoscopic “pinholes” in bacterial cell membranes to induce cell lysis as part of the viral replication cycle. Pinholin can transition from an inactive to an active conformation by exposing a transmembrane domain (TMD1) to the extracellular fluid. Upon activation, several copies of the protein assemble via interactions among a second transmembrane domain (TMD2) to form a single pore, thus hastening cell lysis and viral escape. The following experiments provide conformational descriptors of pinholin in active and inactive states and elucidate the molecular driving forces that control pinholin activity. In the present study, molecular dynamics (MD) simulations have been used to refine experimentally derived conformational descriptors into an atomistically detailed model of irsS2168, an antiholin mutant. To provide additional details about the thermodynamics of pinholin activation and to overcome large intrinsic kinetic barriers to activation, alchemical free energy simulations have been conducted. Alchemical mutations reveal the change in folding free energy upon mutation. The results suggest that alchemical mutations are an effective tool to rationalize experimental observations and predict the effects of site mutations on conformational states for proteins integrated into lipid bilayers. S16F, A17Q, A17Q+G21Q, and A17Q+G21Q+G14Q mutants reveal how changes in hydrophilicity and disruption of the glycine zipper motif influence pinholin’s thermodynamic equilibrium, favoring the active conformation. These findings align with experimental observations from DEER spectroscopy, demonstrating that mutations increasing the hydrophilicity of TMD1 promote activation by making TMD1 more likely to exit the membrane and enter the extracellular fluid.
- Published
- 2024
- Full Text
- View/download PDF
39. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
- Author
-
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, and Andrew M Haydon
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated with differences in TMB. However the impact of this on the effectiveness of immune CPIs is unknown. We examined the efficacy of CPIs in acral melanoma, including by primary site.Methods Patients with unresectable stage III/IV acral melanoma treated with CPI (anti-PD-1 and/or ipilimumab) were studied. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS).Results In total, 325 patients were included: 234 (72%) plantar, 69 (21%) subungual and 22 (7%) palmar primary sites. First CPI included: 184 (57%) anti-PD-1, 59 (18%) anti-PD-1/ipilimumab combination and 82 (25%) ipilimumab. ORR was significantly higher with initial anti-PD-1/ipilimumab compared with anti-PD-1 (43% vs 26%, HR 2.14, p=0.0004) and significantly lower with ipilimumab (15% vs 26%, HR 0.49, p=0.0016). Landmark PFS at 1 year was highest for anti-PD-1/ipilimumab at 34% (95% CI 24% to 49%), compared with 26% (95% CI 20% to 33%) with anti-PD-1 and 10% (95% CI 5% to 19%) with ipilimumab. Despite a trend for increased PFS, anti-PD-1/ipilimumab combination did not significantly improve PFS (HR 0.85, p=0.35) or OS over anti-PD-1 (HR 1.30, p=0.16), potentially due to subsequent therapies and high rates of acquired resistance. No outcome differences were found between primary sites.Conclusion While the ORR to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and PFS numerically higher, in this retrospective cohort this benefit did not translate to improved OS. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.
- Published
- 2022
- Full Text
- View/download PDF
40. Probing Structural Dynamics of Membrane Proteins Using Electron Paramagnetic Resonance Spectroscopic Techniques
- Author
-
Indra D. Sahu and Gary A. Lorigan
- Subjects
embrane protein ,electron paramagnetic resonance (EPR) ,site-directed spin labeling (SDSL) ,double electron electron resonance (DEER) ,structural topology and dynamics ,Biology (General) ,QH301-705.5 - Abstract
Membrane proteins are essential for the survival of living organisms. They are involved in important biological functions including transportation of ions and molecules across the cell membrane and triggering the signaling pathways. They are targets of more than half of the modern medical drugs. Despite their biological significance, information about the structural dynamics of membrane proteins is lagging when compared to that of globular proteins. The major challenges with these systems are low expression yields and lack of appropriate solubilizing medium required for biophysical techniques. Electron paramagnetic resonance (EPR) spectroscopy coupled with site directed spin labeling (SDSL) is a rapidly growing powerful biophysical technique that can be used to obtain pertinent structural and dynamic information on membrane proteins. In this brief review, we will focus on the overview of the widely used EPR approaches and their emerging applications to answer structural and conformational dynamics related questions on important membrane protein systems.
- Published
- 2021
- Full Text
- View/download PDF
41. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
- Author
-
Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Keilholz, U.
- Published
- 2020
- Full Text
- View/download PDF
42. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
- Author
-
Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Michielin, O.
- Published
- 2020
- Full Text
- View/download PDF
43. Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
- Author
-
Lorigan, Paul, Medina, Theresa, Nyakas, Marta, Rutten, Annemie, Feun, Lynn G., Cowey, Charles Lance, Payne, Miranda, Hussain, Israr, Kuzel, Timothy, O'Day, Steven, Sheri, Amna, Friedlander, Philip Adam, Kumar, Satish, Bjorheim, Jens, and Bechter, Oliver Edgar
- Published
- 2024
- Full Text
- View/download PDF
44. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF -V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
- Author
-
Robert, Caroline, Dutriaux, Caroline, Oppong, Felix Boakye, Kicinski, Michal, Routier, Emilie, Neidhardt, Eve-Marie, Durando, Xavier, Baroudjian, Barouyr, Saiag, Philippe, Gaudy-Marqueste, Caroline, Ascierto, Paolo Antonio, Arance, Ana Maria, Russillo, Michelangelo, Perrot, Jean-Luc, Govaerts, Anne-sophie, Bührer, Emanuel, Schilling, Bastian, Mandala, Mario, Lorigan, Paul, and van Akkooi, Alexander Christopher Jonathan
- Published
- 2024
- Full Text
- View/download PDF
45. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement
- Author
-
Peach, H., Board, R., Cook, M., Corrie, P., Ellis, S., Geh, J., King, P., Laitung, G., Larkin, J., Marsden, J., Middleton, M., Moncrieff, M., Nathan, P., Powell, B., Pritchard-Jones, R., Rodwell, S., Steven, N., and Lorigan, P.
- Published
- 2020
- Full Text
- View/download PDF
46. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
- Author
-
Cooksley, T, primary, Weaver, J, additional, McNamara, M, additional, and Lorigan, P, additional
- Published
- 2024
- Full Text
- View/download PDF
47. Vemurafenib in patients with BRAF(V600) mutation-positive meta-static melanoma: final overall survival results of the BRIM-3 study
- Author
-
Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo Antonio, Testori, Alessandro, Lorigan, Paul, Dummer, Reinhard, Sosman, Jeffrey A, Flaherty, Keith T, Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, and McArthur, Grant A
- Subjects
Immunology ,Medical and Health Sciences - Published
- 2016
48. Melanoma and immunotherapy bridge 2015
- Author
-
Nanda, Vashisht GY, Peng, Weiyi, Hwu, Patrick, Davies, Michael A, Ciliberto, Gennaro, Fattore, Luigi, Malpicci, Debora, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Croce, Carlo M, Mancini, Rita, Spranger, Stefani, Gajewski, Thomas F, Wang, Yangyang, Ferrone, Soldano, Vanpouille-Box, Claire, Wennerberg, Erik, Pilones, Karsten A, Formenti, Silvia C, Demaria, Sandra, Tang, Haidong, Wang, Yang, Fu, Yang-Xin, Dummer, Reinhard, Puzanov, Igor, Tarhini, Ahmad, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sanders, Cindy, Kirkwood, John M, Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J, Zarour, Hassane M, Stroncek, David F, Huber, Veronica, Rivoltini, Licia, Thurin, Magdalena, Rau, Tilman, Lugli, Alessandro, Pagès, Franck, Camarero, Jorge, Sancho, Arantxa, Jommi, Claudio, de Coaña, Yago Pico, Wolodarski, Maria, Yoshimoto, Yuya, Gentilcore, Giusy, Poschke, Isabel, Masucci, Giuseppe V, Hansson, Johan, Kiessling, Rolf, Scognamiglio, Giosuè, Sabbatino, Francesco, Marino, Federica Zito, Anniciello, Anna Maria, Cantile, Monica, Cerrone, Margherita, Scala, Stefania, D’alterio, Crescenzo, Ianaro, Angela, Cirin, Giuseppe, Liguori, Giuseppina, Bott, Gerardo, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Ribas, Antoni, Hogg, David, Hamid, Omid, Testori, Alessandro, Lorigan, Paul, Sosman, Jeffrey A, Flaherty, Keith T, Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, McArthur, Grant A, Sznol, Mario, Callahan, Margaret K, Kluger, Harriet, Postow, Michael A, Gordan, RuthAnn, Segal, Neil H, Rizvi, Naiyer A, Lesokhin, Alexander, Atkins, Michael B, Burke, Matthew M, Ralabate, Amanda, Rivera, Angel, Kronenberg, Stephanie A, Agunwamba, Blessing, Ruisi, Mary, Horak, Christine, and Jiang, Joel
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Clinical Research ,Cancer ,Good Health and Well Being ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh
- Published
- 2016
49. Survival of patients with advanced metastatic melanoma: The impact of novel therapies
- Author
-
Ugurel, Selma, Röhmel, Joachim, Ascierto, Paolo A, Flaherty, Keith T, Grob, Jean Jacques, Hauschild, Axel, Larkin, James, Long, Georgina V, Lorigan, Paul, McArthur, Grant A, Ribas, Antoni, Robert, Caroline, Schadendorf, Dirk, and Garbe, Claus
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Antibodies ,Monoclonal ,Antineoplastic Agents ,Clinical Trials as Topic ,Drug Therapy ,Combination ,Humans ,Ipilimumab ,Kaplan-Meier Estimate ,Melanoma ,Molecular Targeted Therapy ,Neoplasm Metastasis ,Protein Kinase Inhibitors ,Skin Neoplasms ,Therapies ,Investigational ,Therapy ,Kinase inhibitors ,Immune checkpoint blockers ,Survival ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
The survival of advanced metastatic melanoma has been greatly improved within the past few years. New therapeutic strategies like kinase inhibitors for BRAF-mutant melanoma and immune checkpoint blockers proved to prolong survival times within clinical trials, and many of them have already entered routine clinical use. However, these different treatment modalities have not yet been tested against each other, which complicate therapy decisions. We performed an explorative analysis of survival data from recent clinical trials. Thirty-five Kaplan-Meier survival curves from 17 trials were digitised, re-grouped by matching inclusion criteria and treatment line, and averaged by therapy strategy. Notably, the survival curves grouped by therapy strategy revealed a very high concordance, even if different agents were used. The greatest survival improvement was observed with the combination of BRAF plus MEK inhibitors as well as with Programmed-death-1 (PD1) blockers with or without cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockers, respectively, with these two treatment strategies showing similar survival outcomes. For first-line therapy, averaged survival proportions of patients alive at 12 months were 74.5% with BRAF plus MEK inhibitor treatment versus 71.9% with PD-1 blockade. This explorative comparison shows the kinase inhibitors as similarly effective as immune checkpoint blockers with regard to survival. However, to confirm these first trends for implementation into an individualised treatment of melanoma patients, data from prospective clinical trials comparing the different treatment strategies head-to-head have to be awaited.
- Published
- 2016
50. Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
- Author
-
Ascierto, Paolo A, Atkins, Michael, Bifulco, Carlo, Botti, Gerardo, Cochran, Alistair, Davies, Michael, Demaria, Sandra, Dummer, Reinhard, Ferrone, Soldano, Formenti, Silvia, Gajewski, Thomas F, Garbe, Claus, Khleif, Samir, Kiessling, Rolf, Lo, Roger, Lorigan, Paul, Arthur, Grant Mc, Masucci, Giuseppe, Melero, Ignacio, Mihm, Martin, Palmieri, Giuseppe, Parmiani, Giorgio, Puzanov, Igor, Romero, Pedro, Schilling, Bastian, Seliger, Barbara, Stroncek, David, Taube, Janis, Tomei, Sara, Zarour, Hassane M, Testori, Alessandro, Wang, Ena, Galon, Jérôme, Ciliberto, Gennaro, Mozzillo, Nicola, Marincola, Francesco M, and Thurin, Magdalena
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Vaccine Related ,Immunization ,Clinical Research ,Cancer ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Good Health and Well Being ,Biomarkers ,Tumor ,Humans ,Immunotherapy ,Italy ,Melanoma ,Tumor Microenvironment ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
The fourth "Melanoma Bridge Meeting" took place in Naples, December 3-6th, 2014. The four topics discussed at this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent advances in tumor biology and immunology have led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded promising results. These include inhibitors of receptor tyrosine kinases (BRAF, MEK, and VEGFR), the phosphatidylinositol 3 kinase (PI3K) pathway [PI3K, AKT, mammalian target of rapamycin (mTOR)], activators of apoptotic pathway, and the cell cycle inhibitors (CDK4/6). Various locoregional interventions including radiotherapy and surgery are still valid approaches in treatment of advanced melanoma that can be integrated with novel therapies. Intrinsic, adaptive and acquired resistance occur with targeted therapy such as BRAF inhibitors, where most responses are short-lived. Given that the reactivation of the MAPK pathway through several distinct mechanisms is responsible for the majority of acquired resistance, it is logical to combine BRAF inhibitors with inhibitors of targets downstream in the MAPK pathway. For example, combination of BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) have been demonstrated to improve survival compared to monotherapy. Application of novel technologies such sequencing have proven useful as a tool for identification of MAPK pathway-alternative resistance mechanism and designing other combinatorial therapies such as those between BRAF and AKT inhibitors. Improved survival rates have also been observed with immune-targeted therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demonstrate clinical benefit in patients with melanoma as well. These agents are being studied in combination with targeted therapies in attempt to produce longer-term responses than those more typically seen with targeted therapy. Other combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates for this patient population. This meeting's specific focus was on advances in combination of targeted therapy and immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment response was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.